Gleiss Lutz advises Coloplast on the acquisition of Atos Medical
A Gleiss Lutz team has advised Danish healthcare company Coloplast on its acquisition of Atos Medical group, the global market leader in laryngectomy, for EUR 2.155 billion (around DKK 16 billion) from PAI Partners, a global private equity firm headquartered in Paris. Closing of the transaction is subject to customary regulatory approvals and anticipated to occur in Q2 2021/22.
Further information on the transaction is available under this link.
The following Gleiss Lutz team, led by Dr Patrick Kaffiné (partner, Frankfurt) and Dr Martin Viciano Gofferje (partner, Berlin, both M&A), advised Coloplast on all aspects of German law in the transaction: Andrej Popp (Frankfurt), Dr Christoph Meissner, Dr Viktor Gorlow (all M&A), Dr Enno Burk (counsel), Dilara Puls (both healthcare, all Berlin), Dr Tim Weber (partner), Maximilian Leisenheimer (both real estate, Frankfurt), Dr Birgit Colbus (counsel, antitrust, Frankfurt), Dr Jacob von Andreae (partner), Matthias Hahn (both regulatory, Dusseldorf), Dr Matthias Werner (counsel), Sebastian Girschick (both IP/IT, Munich), Simon Wegmann (data protection, Berlin), Dr Doris-Maria Schuster (partner), Dr Hauke Darius Wolf (both employment, Hamburg), Dr Matthias Böglmüller (pensions, Munich), Frank Schlobach (partner), Yvonne Gerster (both finance, Frankfurt), Dr Tobias Harzenetter (partner), Dr Julian Aicher (both corporate, Munich), Dr Eike Bicker (partner), Marina von Eicke und Polwitz, Felix Wrocklage (all compliance, Frankfurt).
Kromann Reumert acted as lead counsel for Coloplast.
Gleiss Lutz regularly advises domestic and international corporations and PE investors on investments in the healthcare and life sciences sector, most recently the global pharmaceutical and diagnostics group Roche on its acquisition of TIB Molbiol Group and the family-owned Ritter Group on the sale of the undertaking to US technology group Avantor.
Forward
